细胞周期蛋白依赖性激酶4/6抑制剂治疗激素受体阳性、ERBB2阴性乳腺癌:综述
该综述汇总了CDK4/6抑制剂(哌柏西利、瑞波西利、阿贝西利)联合内分泌治疗用于HR+、ERBB2-晚期或转移性乳腺癌的随机3期研究证据,并指出各药在总生存期、不良反应及高危早期乳腺癌辅助治疗中的差异,强调缺乏预测生物标志物及最佳序贯策略。
要点
- 随机3期研究显示,CDK4/6抑制剂联合内分泌治疗较内分泌单药使疾病进展风险约降低一半。
- 阿贝西利和瑞波西利在高危HR+早期乳腺癌中已显示疗效。
- 除激素受体状态外,缺乏常规使用的CDK4/6抑制剂疗效预测生物标志物。
核心结论
- 未来研究应聚焦于明确每种CDK4/6抑制剂在HR+乳腺癌中的角色,并开发基于生物标志物指导的整合策略。
研究设计与样本
- 综述,基于随机3期研究证据,讨论CDK4/6抑制剂联合内分泌治疗在HR+、ERBB2-乳腺癌中的应用。
主要发现
- 随机3期研究显示,与激素单药(芳香化酶抑制剂、他莫昔芬或氟维司群)相比,加用CDK4/6抑制剂使一线和/或二线治疗中疾病进展的风险比降低约一半。
- 美国食品药品监督管理局和欧洲药品管理局已批准3种CDK4/6抑制剂用于一线和二线治疗。
- 各CDK4/6抑制剂在作用机制、不良反应谱和总生存期方面的差异正在显现。
- 阿贝西利和瑞波西利均在高危HR+早期乳腺癌中显示出疗效。
局限性
- 转移性乳腺癌中总生存期结果存在不一致,辅助治疗中疗效存在差异,其原因尚不清楚。
- 除激素受体状态外,缺乏预测CDK4/6抑制剂联合内分泌治疗反应的生物标志物,且这些标志物未常规使用。
- 部分高度内分泌敏感患者单用内分泌治疗即可获得良好疗效,能否将CDK4/6抑制剂推迟至二线使用尚未解答,尤其当存在经济毒性担忧时。
- 某些CDK4/6抑制剂进展后内分泌反应性缺失,最佳序贯治疗策略仍需确定。
- 未来研究需明确每种CDK4/6抑制剂的作用并开发基于生物标志物的整合策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Combination therapy with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i: palbociclib, ribociclib, abemaciclib) and endocrine therapy (ET) has been a major advance for the treatment of hormone receptor-positive (HR+), ERBB2 (formerly HER2)-negative (ERBB2-) advanced or metastatic breast cancer. OBSERVATIONS: Randomized phase 3 studies demonstrated that the addition of CDK4/6i reduced the hazard risk of disease progression by approximately half compared with hormonal monotherapy (an aromatase inhibitor, tamoxifen, or fulvestrant) in the first-line (1L) and/or second-line (2L) setting. Hence, the US Food and Drug Administration and European Medicines Agency approved 3 CDK4/6i, in both 1L and 2L settings. However, differences among the CDK4/6i regarding mechanisms of action, adverse effect profiles, and overall survival (OS) are emerging. Both abemaciclib and ribociclib have demonstrated efficacy in high-risk HR+ early breast cancer. While ET with or without CDK4/6i is accepted as standard treatment for persons with advanced HR+ ERBB2- metastatic breast cancer, several key issues remain. First, why are there discordances in OS in the metastatic setting and efficacy differences in the adjuvant setting? Additionally, apart from HR status, there are few biomarkers predictive of response to CDK4/6i plus ET, and these are not used routinely. Despite the clear OS advantage noted in the 1L and 2L metastatic setting with some CDK4/6i, a subset of patients with highly endocrine-sensitive disease do well with ET alone. Therefore, an unanswered question is whether some patients can postpone CDK4/6i until the 2L setting, particularly if financial toxicity is a concern. Finally, given the lack of endocrine responsiveness following progression on some CDK4/6i, strategies to optimally sequence treatment are needed. CONCLUSIONS AND RELEVANCE: Future research should focus on defining the role of each CDK4/6i in HR+ breast cancer and developing a biomarker-directed integration of these agents.
引用
- O'Sullivan CC, Clarke R, Goetz MP, et al. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review. JAMA Oncol. 2023. PMID: 37382948. doi:10.1001/jamaoncol.2023.2000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。